portal hypertension
Conditions
Interventions
Group 4:rifaximin+long acting octreotide
Group 2:rifaximin
Group 3:long acting octreotide
Sponsors
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. willing to sign informed consent; 2. The age ranged from 18 to 75 years, with no gender limitation; 3. any causes of cirrhosis portal hypertension; 4. gastroscopy or barium meal examination confirmed esophageal varices; 5. liver function Child-Pugh grade B or C grade, which lasted for more than 1 month.
Exclusion criteria
Exclusion criteria: 1. In the past 2 weeks, there were confirmed or suspected esophageal varices bleeding; 2. Changes of antiviral drugs in recent 30days (including newly adopting, stopping or switching to other drugs); 3. In recent months, suffering moderate to severe hepatic encephalopathy, esophagogastric variceal bleeding or spontaneous bacterial peritonitis occurred. 4. The titer of hepatitis B virus is more than 1000 copy/ml; 5. Patients with obvious cardiopulmonary disease, or the basal heart rate is less than 70 beats / min, or the basal blood pressure is lower than 100 / 70 mmHg; 6. Obvious renal impairment (serum creatinine was more than 2 mg/dL or glomerular filtration rate GFR20 ng/ml) should be excluded by CT and other examinations; 8. HIV infection; 9. Allergic to long acting octreotide and / or rifaximin; 10. Women who are pregnant or lactation or who do not exclude pregnancy may not be suitable for participants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CT;MRI;ultrasonography; | — |
Secondary
| Measure | Time frame |
|---|---|
| liver function;Blood ammonia; | — |
Countries
China
Contacts
Public ContactGuan Jiao
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Outcome results
None listed